These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 25486467)

  • 1. Upgrading gemcitabine with recycled kinase inhibitors.
    Blanco FF; Pishvaian MJ; Brody JR
    Cell Cycle; 2014; 13(18):2810-1. PubMed ID: 25486467
    [No Abstract]   [Full Text] [Related]  

  • 2. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
    Beeharry N; Banina E; Hittle J; Skobeleva N; Khazak V; Deacon S; Andrake M; Egleston BL; Peterson JR; Astsaturov I; Yen TJ
    Cell Cycle; 2014; 13(14):2172-91. PubMed ID: 24955955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer.
    Chung S; Vail P; Witkiewicz AK; Knudsen ES
    Clin Cancer Res; 2019 Apr; 25(7):2290-2304. PubMed ID: 30538111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.
    Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY
    Mol Cancer Ther; 2015 Feb; 14(2):407-18. PubMed ID: 25519702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
    Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel multi‑kinase inhibitor, T03 inhibits Taxol‑resistant breast cancer.
    Li Y; Liu C; Tang K; Chen Y; Tian K; Feng Z; Chen J
    Mol Med Rep; 2018 Feb; 17(2):2373-2383. PubMed ID: 29207185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phytochemicals, withaferin A and carnosol, overcome pancreatic cancer stem cells as c-Met inhibitors.
    Aliebrahimi S; Kouhsari SM; Arab SS; Shadboorestan A; Ostad SN
    Biomed Pharmacother; 2018 Oct; 106():1527-1536. PubMed ID: 30119228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ponatinib Inhibits Proliferation and Induces Apoptosis of Liver Cancer Cells, but Its Efficacy Is Compromised by Its Activation on PDK1/Akt/mTOR Signaling.
    Liu C; Mu X; Wang X; Zhang C; Zhang L; Yu B; Sun G
    Molecules; 2019 Apr; 24(7):. PubMed ID: 30959969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
    Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
    Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
    Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
    Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinase inhibitor conjugates.
    Harmsen S; Kok RJ
    Curr Pharm Des; 2012; 18(20):2891-900. PubMed ID: 22571658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
    Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
    Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focus issue: Rendering resistance futile.
    Adler EM; Gough NR
    Sci Signal; 2011 Mar; 4(166):eg3. PubMed ID: 21447795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethacrynic acid improves the antitumor effects of irreversible epidermal growth factor receptor tyrosine kinase inhibitors in breast cancer.
    Liu B; Huang X; Hu Y; Chen T; Peng B; Gao N; Jin Z; Jia T; Zhang N; Wang Z; Jin G
    Oncotarget; 2016 Sep; 7(36):58038-58050. PubMed ID: 27487128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
    Liu H; Zhang T; Chen R; McConkey DJ; Ward JF; Curley SA
    J Surg Res; 2012 Jul; 176(1):147-53. PubMed ID: 22099584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.
    Mu C; Wu X; Ma H; Tao W; Zhang G; Xia X; Shen J; Mai J; Sun T; Sun X; Arlinghaus RB; Shen H
    Mol Cancer Ther; 2016 May; 15(5):899-910. PubMed ID: 26846820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
    Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
    Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.